Applied Genomics, Clarient deal

Clarient will acquire diagnostic company Applied Genomics in a stock deal valued at $11 million, based on Clarient's close of $2.49 on Dec. 18, 2009, the last trading day before the deal was announced. Applied Genomics shareholders will receive 4.4 million shares up front and are eligible for 3.2 million shares in clinical, commercial and revenue milestones. Aquilo Partners L.P. advised Applied Genomics. ...